Pacific Biosciences of California Inc. [NASDAQ: PACB] price surged by 0.39 percent to reach at $0.02. The company report on June 27, 2022 that PacBio Grants Equity Incentive Award to New Employee.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 100,000 shares of PacBio common stock, and restricted stock units (“RSUs”) covering 50,000 shares of PacBio common stock, to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the “2020 Inducement Plan”) effective on June 21, 2022.
The 2020 Inducement Plan is used exclusively to grant equity awards to individuals who were not previously an employee or non-employee director of PacBio as an inducement material to such individual’s entering into employment with PacBio in accordance with Nasdaq Marketplace Rule 5635(c)(4).
A sum of 3900956 shares traded at recent session while its average daily volume was at 7.13M shares. Pacific Biosciences of California Inc. shares reached a high of $5.25 and dropped to a low of $4.85 until finishing in the latest session at $5.12.
The one-year PACB stock forecast points to a potential upside of 66.75. The average equity rating for PACB stock is currently 2.30, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Pacific Biosciences of California Inc. [PACB]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PACB shares is $15.40 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PACB stock is a recommendation set at 2.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Cantor Fitzgerald have made an estimate for Pacific Biosciences of California Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on January 21, 2022. While these analysts kept the previous recommendation, Piper Sandler raised their target price to Neutral. The new note on the price target was released on January 06, 2022, representing the official price target for Pacific Biosciences of California Inc. stock. Previously, the target price had yet another raise to $30, while Cowen analysts kept a Market Perform rating on PACB stock.
The Average True Range (ATR) for Pacific Biosciences of California Inc. is set at 0.47, with the Price to Sales ratio for PACB stock in the period of the last 12 months amounting to 8.76. The Price to Book ratio for the last quarter was 1.55, with the Price to Cash per share for the same quarter was set at 4.18.
PACB Stock Performance Analysis:
Pacific Biosciences of California Inc. [PACB] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.58. With this latest performance, PACB shares gained by 19.63% in over the last four-week period, additionally sinking by -69.12% over the last 6 months – not to mention a drop of -82.74% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PACB stock in for the last two-week period is set at 50.49, with the RSI for the last a single of trading hit 52.23, and the three-weeks RSI is set at 48.23 for Pacific Biosciences of California Inc. [PACB]. The present Moving Average for the last 50 days of trading for this stock 5.23, while it was recorded at 5.23 for the last single week of trading, and 13.89 for the last 200 days.
Insight into Pacific Biosciences of California Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Pacific Biosciences of California Inc. [PACB] shares currently have an operating margin of -136.51 and a Gross Margin at +45.04. Pacific Biosciences of California Inc.’s Net Margin is presently recorded at -138.85.
Return on Equity for this stock declined to -32.18, with Return on Assets sitting at -14.97.
Pacific Biosciences of California Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 16.40 and a Current Ratio set at 16.90.
PACB Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PACB. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Pacific Biosciences of California Inc. go to -1.00%.
Pacific Biosciences of California Inc. [PACB] Insider Position Details
There are presently around $1,147 million, or 95.30% of PACB stock, in the hands of institutional investors. The top three institutional holders of PACB stocks are: ARK INVESTMENT MANAGEMENT LLC with ownership of 28,045,530, which is approximately 2.883% of the company’s market cap and around 0.70% of the total institutional ownership; JACKSON SQUARE PARTNERS, LLC, holding 22,542,589 shares of the stock with an approximate value of $114.97 million in PACB stocks shares; and VANGUARD GROUP INC, currently with $101.72 million in PACB stock with ownership of nearly 0.454% of the company’s market capitalization.
Positions in Pacific Biosciences of California Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 137 institutional holders increased their position in Pacific Biosciences of California Inc. [NASDAQ:PACB] by around 42,567,569 shares. Additionally, 118 investors decreased positions by around 23,632,101 shares, while 37 investors held positions by with 158,783,059 shares. The mentioned changes placed institutional holdings at 224,982,729 shares, according to the latest SEC report filing. PACB stock had 42 new institutional investments in for a total of 7,987,697 shares, while 51 institutional investors sold positions of 8,191,610 shares during the same period.